Cargando…
Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting
RATIONALE: Murine syngeneic tumor models have revealed efficacious systemic antitumor responses following primary tumor in situ vaccination combined with targeted radionuclide therapy to secondary or metastatic tumors. Here we present studies on the safety and feasibility of this approach in a relev...
Autores principales: | Magee, Kara, Marsh, Ian R., Turek, Michelle M., Grudzinski, Joseph, Aluicio-Sarduy, Eduardo, Engle, Jonathan W., Kurzman, Ilene D., Zuleger, Cindy L., Oseid, Elizabeth A., Jaskowiak, Christine, Albertini, Mark R., Esbona, Karla, Bednarz, Bryan, Sondel, Paul M., Weichert, Jamey P., Morris, Zachary S., Hernandez, Reinier, Vail, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360580/ https://www.ncbi.nlm.nih.gov/pubmed/34383787 http://dx.doi.org/10.1371/journal.pone.0255798 |
Ejemplares similares
-
Antitumor efficacy of (90)Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors
por: Potluri, Hemanth K, et al.
Publicado: (2022) -
(177)Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer
por: Hernandez, Reinier, et al.
Publicado: (2020) -
(90)Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin’s Lymphoma
por: Hernandez, Reinier, et al.
Publicado: (2019) -
Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
por: Kerr, Caroline P., et al.
Publicado: (2022) -
Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy
por: Jagodinsky, Justin C., et al.
Publicado: (2021)